You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)雙抗體療法III期臨床試驗達主要研究終點
阿思達克 01-27 05:03
君實生物(01877.HK)公布,etesevimab 2,800 mg及bamlanivimab2,800 mg雙抗體療法顯著降低了近期被確診為新型冠狀病毒肺炎高重症化風險患者相關住院和死亡事件,達到了BLAZE-1研究III期臨床試驗的主要研究終點。

在III期試驗中,etesevimab及bamlanivimab雙抗體療法的安全性特徵與評估該等抗體的其他I期、II期及III期試驗觀察結果一致。

試驗結果顯示,etesevimab在預防及治療新冠病毒感染方面均具有良好療效。公司與中科院微生物所共同開發該新冠病毒中和抗體後,禮來製藥從公司引進etesevimab。其中,公司主導大中華地區的開發活動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account